drugset / Trial / NCT06874335
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1, first in human (FIH), Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination with Other Anti-Cancer Agents in Adult Participants with Advanced or Metastatic Solid Tumors
Timeline
- Start
- 2025-03-20
- Primary completion
- 2029-03
- Completion
- 2029-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BHV-1530 | Unknown | — | Intravenous |
| Subject | Cemiplimab | Monoclonal antibody | 350 mg | Intravenous |